Masimo Croissance future

Future contrôle des critères 3/6

Masimo devrait augmenter ses bénéfices et ses revenus de 29.6% et de 6% par an respectivement, tandis que le BPA devrait croître de croître de 29.5% par an.

Informations clés

29.6%

Taux de croissance des bénéfices

29.5%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.1%
Taux de croissance des recettes	6.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	06 Nov 2024

Mises à jour récentes de la croissance future

Analyst Estimates: Here's What Brokers Think Of Masimo Corporation (NASDAQ:MASI) After Its First-Quarter Report

May 10

Recent updates

Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 44% Undervaluation?

Nov 07

Analyst Estimates: Here's What Brokers Think Of Masimo Corporation (NASDAQ:MASI) After Its First-Quarter Report

May 10

Baron Funds - Masimo Corp.: Can Potentially Double Our Investment

May 05

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Apr 13

Masimo Corporation's (NASDAQ:MASI) Popularity With Investors Is Under Threat From Overpricing

Mar 28

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 29

Estimating The Intrinsic Value Of Masimo Corporation (NASDAQ:MASI)

Feb 24

Masimo: Given The Lack Of Improvement In Revenues And Margins, It Is A Little Expensive

Feb 18

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Feb 08

Earnings Tell The Story For Masimo Corporation (NASDAQ:MASI) As Its Stock Soars 27%

Dec 23

At US$112, Is It Time To Put Masimo Corporation (NASDAQ:MASI) On Your Watch List?

Dec 14

Masimo Corporation (NASDAQ:MASI) Shares Could Be 38% Below Their Intrinsic Value Estimate

Nov 09

Is Masimo (NASDAQ:MASI) Using Too Much Debt?

Sep 19

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Aug 04

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:MASI - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	2,365	239	395	463	9
12/31/2025	2,220	188	280	351	10
12/31/2024	2,087	95	293	272	10
9/28/2024	2,043	79	150	223	N/A
6/29/2024	2,017	79	111	190	N/A
3/30/2024	1,976	79	51	140	N/A
12/30/2023	2,048	82	6	94	N/A
9/30/2023	2,116	89	-58	10	N/A
7/1/2023	2,187	116	-28	28	N/A
4/1/2023	2,297	118	-45	7	N/A
12/31/2022	2,036	144	-27	29	N/A
10/1/2022	1,746	171	78	134	N/A
7/2/2022	1,505	191	147	205	N/A
4/2/2022	1,244	223	181	229	N/A
1/1/2022	1,239	230	230	265	N/A
10/2/2021	1,207	232	188	232	N/A
7/3/2021	1,177	224	149	190	N/A
4/3/2021	1,173	229	176	228	N/A
1/2/2021	1,144	240	131	211	N/A
9/26/2020	1,096	223	138	217	N/A
6/27/2020	1,047	222	148	227	N/A
3/28/2020	976	211	119	222	N/A
12/28/2019	938	196	149	222	N/A
9/28/2019	913	190	150	215	N/A
6/29/2019	895	198	153	212	N/A
3/30/2019	877	197	187	210	N/A
12/29/2018	858	194	217	240	N/A
9/29/2018	843	139	201	225	N/A
6/30/2018	826	118	N/A	199	N/A
3/31/2018	807	119	N/A	114	N/A
12/30/2017	790	125	N/A	56	N/A
9/30/2017	766	348	N/A	338	N/A
7/1/2017	740	340	N/A	347	N/A
4/1/2017	720	325	N/A	414	N/A
12/31/2016	713	311	N/A	419	N/A
10/1/2016	672	109	N/A	150	N/A
7/2/2016	657	101	N/A	145	N/A
4/2/2016	640	90	N/A	117	N/A
1/2/2016	623	83	N/A	117	N/A
10/3/2015	623	80	N/A	85	N/A
7/4/2015	613	76	N/A	86	N/A
4/4/2015	596	70	N/A	91	N/A
1/3/2015	580	73	N/A	96	N/A
9/27/2014	556	61	N/A	73	N/A
6/28/2014	545	61	N/A	61	N/A
3/29/2014	543	65	N/A	54	N/A
12/28/2013	541	58	N/A	55	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MASI ( 29.6% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de MASI ( 29.6% par an) devraient croître plus rapidement que le marché US ( 15.3% par an).

Croissance élevée des bénéfices: Les bénéfices de MASI devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de MASI ( 6% par an) devrait croître plus lentement que le marché de US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de MASI ( 6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MASI devrait être élevé dans 3 ans

Masimo Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Masimo Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Masimo Corporation Provides Earnings Guidance for the Third-Quarter and Full-Year 2024

Analyst Estimates: Here's What Brokers Think Of Masimo Corporation (NASDAQ:MASI) After Its First-Quarter Report

Masimo Corporation Provides Earnings Guidance for the Second Quarter 2024 and Updates Earnings Guidance for the Full-Year 2024

Price target increased by 12% to US$135

Masimo Corporation Reaffirms Financial Guidance for the First Quarter and Fiscal Year 2024

Recent updates

Insider exercised options and sold US$2.3m worth of stock

New minor risk - Financial position

Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 44% Undervaluation?

Third quarter 2024 earnings: EPS misses analyst expectations

Masimo Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Masimo Corporation to Report Q3, 2024 Results on Nov 05, 2024

Masimo Corporation Announces Board of Directors Appointments

Masimo Corporation's (NASDAQ:MASI) 28% Share Price Surge Not Quite Adding Up

High number of new and inexperienced directors

Masimo Corporation Announces CEO Changes

Masimo Corporation: Too Much Uncertainty For Now

Politan Capital Comments on Results of Masimo’s Annual Meeting

Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote

Politan Capital Issues Statement from Legal Advisors Schulte Roth & Zabel and Munger, Tolles & Olson Regarding Masimo Corporation Proxy Contest

Politan Provides Update on Why Masimo Shareholders Should Support Urgently Needed Board Change at Company’s 2024 AGM

Founder exercised options to buy US$29m worth of stock.

Masimo W1 Medical Watch Receives Fda 510(K) Clearance for Connectivity to the Masimo Safetynet Telemonitoring System

Second quarter 2024 earnings: EPS exceeds analyst expectations

Masimo Corporation Provides Earnings Guidance for the Third-Quarter and Full-Year 2024

What Is Masimo Corporation's (NASDAQ:MASI) Share Price Doing?

Masimo Announces New Study Finds That Remote Patient Monitoring with Masimo Safetynet® Significantly Reduced Rates of Hospital Readmission and Ed Visits for Patients Recuperating At Home After Joint Replacement Surgery

Masimo Corporation to Report Q2, 2024 Results on Aug 06, 2024

Politan Capital Management Files a Lawsuit in the Delaware Court of Chancery Against Masimo Corporation

Politan Capital Issues Response to Masimo Corporation’s Annual Meeting Change

Politan Capital Management Sends a Letter to the Board of Masimo Corporation

Masimo Corporation's (NASDAQ:MASI) Share Price Matching Investor Opinion

Masimo Corporation Announces Class Action Lawsuit Filed on Behalf of Investors

Politan Capital Sends a Letter to the Board of Masimo Corporation

Politan Capital Issues Investor Presentation with Shareholders of Masimo Corporation

Masimo Corporation Removes Joe Kiani as the Chief Executive Officer

Politan Capital Sends a Letter to Shareholders of Masimo Corporation

Masimo Corporation, Annual General Meeting, Jul 25, 2024

Masimo Corporation, Annual General Meeting, Jul 25, 2024

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Masimo Corporation Provides Update on Voluntary Recall of Select Rad-G Products

Masimo Corporation Announces Changes to its Board

Masimo and Denon Introduces White PerL and PerL Pro™ Earbuds

Investor sentiment deteriorates as stock falls 16%

Masimo: Promising Developments

Analyst Estimates: Here's What Brokers Think Of Masimo Corporation (NASDAQ:MASI) After Its First-Quarter Report

Politan Capital Management Threatens Masimo Corporation with Legal Action

Masimo Corporation Provides Earnings Guidance for the Second Quarter 2024 and Updates Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Masimo Receives FDA Clearance for Stork Over-the-Counter (OTC) Baby Monitoring System

Baron Funds - Masimo Corp.: Can Potentially Double Our Investment

Lead Independent Director notifies of intention to sell stock

Masimo Corporation to Report Q1, 2024 Results on May 07, 2024

Is There Now An Opportunity In Masimo Corporation (NASDAQ:MASI)?

Masimo Corporation's (NASDAQ:MASI) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 12% to US$135

Masimo Corporation Reaffirms Financial Guidance for the First Quarter and Fiscal Year 2024

Masimo Corporation(NasdaqGS:MASI) dropped from FTSE All-World Index (USD)

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth-Quarter and Full-Year 2024

Masimo Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 13% to US$128

Estimating The Intrinsic Value Of Masimo Corporation (NASDAQ:MASI)

Now 20% undervalued

Masimo: Given The Lack Of Improvement In Revenues And Margins, It Is A Little Expensive

Masimo Corporation Announces Board Changes

Masimo Announces the First FDA-Cleared “Over-The-Counter” Fingertip Pulse Oximeter

These 4 Measures Indicate That Masimo (NASDAQ:MASI) Is Using Debt Extensively

Masimo Corporation to Report Q4, 2023 Results on Feb 27, 2024

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

Masimo Corporation Appoints Bob Chapek to the Board of Directors

Price target increased by 17% to US$108

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth Quarter and Full Year Ended December 30, 2023 and Full Year 2024

Earnings Tell The Story For Masimo Corporation (NASDAQ:MASI) As Its Stock Soars 27%

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System